Age-related macular degeneration (AMD)

Current Care Summary
Working group appointed by the Finnish Medical Society Duodecim, the Finnish Ophthalmological Society and the University and Central Hospital Ophtalomology Clinics in Finland
2.1.2017

Current Care Guideline in Finnish «Kostea silmänpohjan ikärappeuma (AMD)»1 and Summary in Finnish «Kostea silmänpohjan ikärappeuma»2

Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of the healthcare systems pose challenges for the provision and development of care. In context of these current aspects, we aim to set evidence-based medicine guidelines for diagnosis, treatment and follow-up of patients with wAMD.

Working group appointed by the Finnish Medical Society Duodecim, the Finnish Ophthalmological Society and the University and Central Hospital Ophtalomology Clinics in Finland

Panel:

Kai Kaarniranta (Chair)

Vesa Aaltonen

Nina Hautala

Ilkka Immonen

Sulevi Kaipiainen

Nina Laitamäki

Marko Ollila

Jari Rantanen

Petri Tommila

Raimo Tuuminen

Hannele Uusitalo-Järvinen

Satu Välimäki

Writers:

Jorma Komulainen

Raija Sipilä

Tanja Laukkala

Specialists:

Kai Kaarniranta

Anja Tuulonen